Interaction Checker

Wechselwirkungen von Naldemedin

Naldemedin (Symproic), ein Opioidantagonist, hat in den von uns erfassten FDA-Fachinformationen und Faktenblättern 118 dokumentierte Wechselwirkungen: 75 schwerwiegende, 41 mittelschwere, 0 geringfügige und 2, bei denen eine Fachinformation keine relevante Wechselwirkung berichtet. Jeder Eintrag unten zitiert den Satz, auf dem er beruht. Diese Medikamentenseite ist ein Ausgangspunkt, kein Urteil über Ihre persönliche Situation.

Wechselwirkungen laut Fachinformation

Schwerwiegende Wechselwirkungen (75)

  • AlvimopanOpioidantagonistSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • AprepitantCYP3A4-HemmerSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • ArmodafinilZNS-StimulansSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Belladonna und OpiumOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Bictegravir, Emtricitabin und Tenofoviralafenamidantiretrovirales ArzneimittelSchwerwiegend

    Opioid Antagonist: Naloxegol ↑ naloxegol Avoid use with BIXLENVO; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (Fachinformation zu Bictegravir, Emtricitabin und Tenofoviralafenamid, Arzneimittelwechselwirkungen)

  • BosentanCYP3A4-InduktorSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • BuprenorphinOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Buprenorphin und NaloxonOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Butalbital, Acetylsalicylsäure, Koffein und CodeinBarbituratSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Butalbital, Paracetamol, Koffein und CodeinBarbituratSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • ButorphanolOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • CarbamazepinAntiepileptikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • CenobamatAntiepileptikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • ClobazamBenzodiazepinSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • CodeinOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Darunavirantiretrovirales ArzneimittelSchwerwiegend

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam Co-administration of PREZISTA/ritonavir… (Fachinformation zu Darunavir, Gegenanzeigen)

  • Darunavir und Cobicistatantiretrovirales ArzneimittelSchwerwiegend

    John's wort ( Hypericum perforatum ) Hepatitis C direct acting antiviral: elbasvir/grazoprevir Lipid modifying agents: lomitapide, lovastatin, simvastatin Opioid Antagonist: naloxegol PDE-5 inhibitor: sildenafil when used for treatment of pulmonary arterial hypertension Sedatives/hypnotics: orally administered midazolam, triazolam PREZCOBIX or PREZCOBIX PED is… (Fachinformation zu Darunavir und Cobicistat, Gegenanzeigen)

  • DeferasiroxEisenpräparatSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • DexamethasonKortikosteroidSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Efavirenzantiretrovirales ArzneimittelSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Efavirenz, Lamivudin und Tenofovirantiretrovirales ArzneimittelSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • EluxadolinOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • EslicarbazepinAntiepileptikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Etravirinantiretrovirales ArzneimittelSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • FentanylOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • FosphenytoinAntiepileptikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • GriseofulvinAntimykotikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • HydrocodonOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Hydrocodon und ChlorphenaminOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Hydrocodon und HomatropinOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Hydrocodon und IbuprofenOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Hydrocodon und ParacetamolOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • HydromorphonOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Lenacapavirantiretrovirales ArzneimittelSchwerwiegend

    Opioid Antagonist: naloxegol ↑ naloxegol Avoid use with SUNLENCA; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. (Fachinformation zu Lenacapavir, Arzneimittelwechselwirkungen)

  • LevorphanolOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Lopinavir und Ritonavirantiretrovirales ArzneimittelSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • LorlatinibCYP3A4-InduktorSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • MethadonOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • MethylnaltrexonOpioidantagonistSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • MitapivatCYP3A4-InduktorSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • MitotanCYP3A4-InduktorSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • ModafinilZNS-StimulansSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • MorphinOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • NafcillinPenicillin-AntibiotikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • NalbuphinOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • NalmefenOpioidantagonistSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • NaloxegolOpioidantagonistSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • NaloxonOpioidantagonistSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • NaltrexonOpioidantagonistSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Naltrexon und BupropionOpioidantagonistSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Nevirapinantiretrovirales ArzneimittelSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Nirmatrelvir und RitonavirVirostatikumSchwerwiegend

    …Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor: sildenafil (Revatio ® ) when used for pulmonary arterial hypertension (PAH) • Sedative/hypnotics: triazolam, oral midazolam • Serotonin… (Fachinformation zu Nirmatrelvir und Ritonavir, Gegenanzeigen)

  • OliceridinOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • OxcarbazepinAntiepileptikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • OxycodonOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Oxycodon und ParacetamolOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • OxymorphonOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Paracetamol und CodeinOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Pentazocin und NaloxonOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • PethidinOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • PhenobarbitalBarbituratSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Phentermin und TopiramatZNS-StimulansSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • PhenytoinAntiepileptikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • PrimidonAntiepileptikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Promethazin und CodeinOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • RemifentanilOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • RifabutinAntibiotikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • RifampicinAntibiotikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • RifapentinAntibiotikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Ritonavirantiretrovirales ArzneimittelSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • SuzetriginCYP3A4-InduktorSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • TapentadolOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • TopiramatAntiepileptikumSchwerwiegend

    John's Wort) Clinical Impact Significant decrease in plasma naldemedine concentrations, which may reduce efficacy [see Clinical Pharmacology (12.3) ] Intervention Avoid use of SYMPROIC with strong CYP3A inducers. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • TramadolOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Tramadol und ParacetamolOpioidSchwerwiegend

    Intervention Avoid use of SYMPROIC with another opioid antagonist. (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

Mittelschwere Wechselwirkungen (41)

  • AbrocitinibJAK-InhibitorMittelschwer

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • AmiodaronAntiarrhythmikumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Atazanavirantiretrovirales ArzneimittelMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • CaptoprilACE-HemmerMittelschwer

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • ChinidinAntiarrhythmikumMittelschwer

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • CiclosporinImmunsuppressivumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • CimetidinH2-BlockerMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • ClarithromycinMakrolid-AntibiotikumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Dextromethorphan und Chinidinserotonerges ArzneimittelMittelschwer

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • DiltiazemCalciumkanalblockerMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • DronedaronAntiarrhythmikumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Elvitegravir, Cobicistat, Emtricitabin und Tenofovirantiretrovirales ArzneimittelMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • ErythromycinMakrolid-AntibiotikumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • EverolimusImmunsuppressivumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • FlibanserinZNS-dämpfendes ArzneimittelMittelschwer

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • FluconazolAzol-AntimykotikumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Fosamprenavirantiretrovirales ArzneimittelMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • FosaprepitantCYP3A4-HemmerMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • ImatinibCYP3A4-HemmerMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • IsoniazidAntibiotikumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • ItraconazolAzol-AntimykotikumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • IvacaftorCYP3A4-HemmerMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • KetoconazolAzol-AntimykotikumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • LapatinibP-Glykoprotein-HemmerMittelschwer

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Ledipasvir und SofosbuvirVirostatikumMittelschwer

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • LofexidinAlpha-Adrenozeptor-AgonistMittelschwer

    Oral Naltrexone : Concomitant use may reduce efficacy of oral naltrexone. (Fachinformation zu Lofexidin, Arzneimittelwechselwirkungen)

  • MifepristonCYP3A4-HemmerMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • MirabegronBeta-Adrenozeptor-AgonistMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • NefazodonAntidepressivumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • NilotinibQT-verlängerndes ArzneimittelMittelschwer

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • PalbociclibCYP3A4-HemmerMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • PerampanelAntiepileptikumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • PosaconazolAzol-AntimykotikumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • PropafenonAntiarrhythmikumMittelschwer

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • RanolazinQT-verlängerndes ArzneimittelMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • Sofosbuvir und VelpatasvirVirostatikumMittelschwer

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • SuvorexantSchlaf- und BeruhigungsmittelMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • TicagrelorThrombozytenaggregationshemmerMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • VerapamilCalciumkanalblockerMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • VoriconazolAzol-AntimykotikumMittelschwer

    Moderate (e.g., fluconazole, atazanavir, aprepitant, diltiazem, erythromycin) and Strong (e.g., itraconazole, ketoconazole, clarithromycin, ritonavir, saquinavir) CYP3A Inhibitors Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse… (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

  • ZonisamidAntiepileptikumMittelschwer

    P-glycoprotein (P-gp) Inhibitors (e.g., amiodarone, captopril, cyclosporine, quercetin, quinidine, verapamil) Clinical Impact Increase in plasma naldemedine concentrations [see Clinical Pharmacology (12.3) ] Intervention Monitor for potential naldemedine-related adverse reactions [see Adverse Reactions (6.1) ] . (Fachinformation zu Naldemedin, Arzneimittelwechselwirkungen)

Keine relevante Wechselwirkung berichtet (2)

  • AcamprosatKeine Wechselwirkung

    The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (Fachinformation zu Acamprosat, Arzneimittelwechselwirkungen)

  • Emtricitabin und Tenofovirantiretrovirales ArzneimittelKeine Wechselwirkung

    No clinically significant drug interactions have been either observed or are expected when DESCOVY is combined with the following drugs: buprenorphine, itraconazole, ketoconazole, lorazepam, methadone, midazolam, naloxone, norbuprenorphine, norgestimate/ethinyl estradiol, and sertraline. (Fachinformation zu Emtricitabin und Tenofovir, Arzneimittelwechselwirkungen)

Prüfen Sie Naldemedin gegen alles, was Sie einnehmen. Fügen Sie Ihre gesamte Liste hinzu; alle Paare werden auf einmal geprüft.

Im Wechselwirkungscheck öffnen

Keine medizinische Beratung. Der Schweregrad gibt die Formulierung der Fachinformation wieder, nicht Ihre persönlichen Umstände. Eine als „schwerwiegend“ eingestufte Wechselwirkung kann unter Aufsicht Routine sein, und eine „geringfügige“ kann bei hohen Dosen von Bedeutung sein. Fragen Sie in einer Apotheke nach.